Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.
This is written in the approval document as:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
Citation
Exemestane Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Exemestane | |
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Exemestane | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Exemestane |